Simple Summary When cancer returns after immune checkpoint inhibitor treatment given around curative surgery, clinicians often have little direct evidence to guide the next therapy. This review examines melanoma, non-small-cell lung cancer, renal cell carcinoma, urothelial carcinoma, and triple-negative breast cancer....
F. Petrelli, L. Dottorini, A. Ghidini et al.· Current Oncology· 0 citations
Time-of-day of treatment, seasonality, latitude-related sunlight exposure, vitamin D status, and circadian rhythm integrity are potentially relevant determinants of systemic therapy outcomes.
A. Ghidini, L. Roncari, R. Bukovec et al.· Critical reviews in oncology...· 0 citations
This review synthesizes how nerves and brain activity directly influence tumour growth across multiple diseases—including gliomas, small cell lung cancer, breast cancer, pancreatic cancer, and prostate cancer—and how these neural signals converge with metabolic and drug-resistance pathways that limit the efficacy of co...
F. Petrelli, A. Callea, A. Ghidini et al.· Medical Oncology· 0 citations
Within RCC, bladder cancer, and NSCLC, next-generation PD-(L)1 combinations are reshaping treatment across all disease stages, and the magnitude of benefit, the relevant biomarkers, and the toxicity trade-offs differ substantially by tumor type and by setting.
F. Petrelli, Lara Colombo Zefinetti, A. D'Alessio et al.· Current Oncology Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
